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Abstract 
The synthesis and evaluation of the anticancer activity of 3’-aryl-5’-arylidene-
spiro[3H-indole-3,2’-thiazolidine]-2,4’(1H)-diones  and  spiro[3H-indole-3,2’-thi-
azolidine]-2,4’(1H)-dione-3’-alkanoic acid esters were described. The structure 
of  the  compounds  was  determined by 
1H and 
13C NMR  and their  in vitro 
anticancer activity was tested in the National Cancer Institute. Among the tested 
compounds,  (5'Z)-5'-(benzylidene)-3'-(4-chlorophenyl)spiro[3H-indole-3,2'-thia-
zolidine]-2,4'(1H)-dione  (IIa) and (5'Z)-3'-(4-chlorophenyl)-5'-[4-(1-methylethyl)-
benzylidene]spiro[3H-indole-3,2'-thiazolidine]-2,4'(1H)-dione (IIb) were superior 
to other related compounds. 
Keywords 
Spiro thiazolidinone isatin conjugates • 2,3,5-Trisubstituted 4-thiazolidinones • Anticancer 
activity • Spiro[indole-3,2'-[1,3]thiazolidine] 
Introduction 
Design of new substances based on privileged scaffolds is one of the successful directions 
in drug discovery. According to this approach, the use of thiazolidinones (rhodanine, 2,4-764  D. Kaminskyy et al.:   
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thiazolidinone, hydantoin) and isatin (1H-indole-2,3-dione)  gives access to series of 
compounds with a  broad spectrum of biological activity. Traditionally,  thiazolidinone 
derivatives are of great interest as sources of innovative drug candidates with 
antimicrobial, antiviral, antidiabetic effects etc. [1, 2]. Recently research of thiazolidinone’s 
pharmacological effects became interesting and promising for anticancer agents design 
[3, 4]. Broad spectrum of chemical modifications of the core heterocycles allowed to form 
diverse groups of thiazolidinone based derivatives [1, 3, 5, 6]. One of the above mentioned 
groups, 2,3-disubstituted 4-thiazolidinones [7], possesses the same spectrum of biological 
activity [8] including anticancer activity [9, 10]. 
On the other hand, isatin derivatives are also a well-known class of biological active 
compounds [11]  and thus often used  as the source of new drug candidates including 
anticancer agents [12]. The exploration of  the  isatin scaffold in combination with other 
molecular fragments is an effective approach for the design of drug-like substances [13]. 
The molecular mechanisms of their anticancer action is associated with the affinity to 
tyrosine kinase [14], cyclin-dependent kinases [15], carbonic anhydrase [16], inhibition of 
TNFα [17] etc.  
Combination of these two mentioned scaffolds in one molecule according seems to be a 
promising 'hybrid pharmacophore' approach to new anticancer agents.  Some known 
examples of such hybrid molecules with anticancer activity are shown in figure 1 [18–20]. 
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Fig. 1.   Structure of some isatin-thiazolidinone hybrid molecules with anticancer activity 
and structure of target compounds. 
Dictated by the previous research results of thiazolidinone derivatives, the aim of the 
presented work was to synthesize new 2,3,5-trisubstituted 4-thiazolidinones  bearig an 
isatin fragment and to investigate their anticancer activity.  
   Spiro[Thiazolidinone-Isatin] Conjugates  765 
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Results and Discussion 
Chemistry 
The most convenient method for the synthesis of 2,3-disubstituted-4-thiazolidinones is the 
one-pot three-component reaction of a  primary amine, an  oxo-compound and a  thiolic 
agent. The different reaction conditions, such as long term heating with a dehydrant, using 
an  acylation agent or microwave assistant organic synthesis (MAOS) were described   
[21–28]. Using isatin or its derivatives in this reaction as oxo-compounds allowed to obtain 
spiro[indole-thiazolidinones] [24, 29]. Based on the above mentioned approach we have 
synthesized spirocompounds I in anhydrous benzene (Scheme 1). 
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Sch. 1.   Spiro thiazolidinone-isatin conjugates synthesis. 
Compounds I contain an active methylene group in position C5 of the core ring, which 
opens  wide opportunities for their modification, taking into consideration the critical 
influence of the presence and the nature of the C5-position moieties on biological activity 
[1, 30]. The synthesis of 5-ylidene-4-thiazolidinones is realized in a Knoevenagel reaction 
but  under different conditions. Commonly  applied  conditions (acetic acid and sodium 
acetate as catalyst) are not effective in 2-substituted-4-thiazolidinones because of the low 
reactivity of the methylene group in comparison with rhodanine (2-thioxo-4-thiazolidinone) 
or 2,4-thiazolidinedione derivatives [31, 32]. Therefore,  the reaction was performed in 
iso-propanol with potassium tert-butylate as catalyst. 
One of the facile methods of structure optimization is the introduction of amino acid 
residues into the molecules. Unfortunately, amino acids usage as amine component in the 
one-pot three component reaction (scheme 1) for the synthesis of compound with an 
aliphatic residue in position N3 of the core ring was not effective. For the synthesis of the 
target compounds Ic, Id the MAOS approach was used (Scheme 2). 766  D. Kaminskyy et al.:   
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Sch. 2.   N3-alkyl substituted thiazolidinone-isatin conjugates synthesis. 
The 
1H NMR spectra of compounds I  show two doublets at ~3.80–4.20 ppm of the 
thiazolidine methylene group. The chemical shift of the methylidene group of the 
5-arylidenederivatives (II) is insignificantly displaced in the weak magnetic field ~7.40–8.00 
ppm, and clearly indicates that only the Z-isomers were obtained [1, 30].  
Biological activity 
Newly synthesized compounds were selected by the National Cancer Institute (NCI) 
Developmental Therapeutic Program (www.dtp.nci.nih.gov) for the in vitro  cell line 
screening to investigate their anticancer activity. Anticancer assays were performed 
according to the US NCI protocol [33–36]. The compounds were first evaluated at one 
dose primary anticancer assay towards 60 cancer lines (concentration 10
−5  M). The 
human tumor cell lines were derived from nine different cancer types: leukemia, 
melanoma, lung, colon, CNS, ovarian, renal, prostate and breast cancers. In the screening 
protocol, each cell line was inoculated and pre-incubated for 24–48 h on a microtiter plate. 
Test agents were then added and the culture was incubated for further 48 h. End point 
determinations were made with a protein binding dye, sulforhodamine B (SRB). Results for 
each test agent were reported as the percent growth of the treated cells when compared to 
the untreated control cells. The preliminary screening results are shown in Table 1. 
The tested compounds showed different levels of anticancer activity and possessed the 
significant specific influence on some cancer cell lines. This activity pattern appeared 
probably due to distinctive molecular mechanisms of action of the mentioned substances. 
Among the tested cancer cell lines, the leukemia panel is the most susceptible to IIa, IIb 
and IIc influence. This action probably may be considered as a 4-thiazolidinones group 
feature [3, 30]. Compounds Ic, Id, IIe and IIf, do not possess significant anticancer action 
and therefore probably are not perspective substances for anticancer agents design. 
Nevertheless, compounds IIa, IIb, IIc and Ic specifically restrained the growth of UO-31 
cancer line (renal cancer) in comparison with other cell lines. This specific pattern was 
observed under the action of related thiazolidinone derivatives [4, 30, 37, 38]. More 
prominent antiproliferative effect of IIa, IIc, IIe, IIf and Ic on SNB-75 cell line (CNS cancer) 
was detected as well. Elongation of  the hydrocarbon chain in position N3  leaded  to a 
decreasing activity level (comparison of activity pattern of Ic and Id). 
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Tab. 1.   Cytotoxic activity of the tested compounds in concentration 10
−5 M against 60 
cancer cell lines 
Cpd.  Mean 
growth, % 
Range of 
growth, % 
Most sensitive cell 
line growth, % (cancer line/type) 
Ic  100.28  62.59–125.39  67.15 (SR/L); 
62.59 (UO-31/RC) 
Id  121.87  76.53–170.75  76.53 (SR/L) 
IIa  55.72  1.78–89.28 
24.52 (A549/ATCC/NSCLC);  
39.71 (BT-49/BC);  
1.78 (T-47D/BC);  
31.30 (CCRF-CEM/L);  
20.25 (HL-60(TB)/L);  
33.28 (K-562/L);  
10.67 (MOLT-4/L); 1 
1.84 (RPMI-8226/L);  
10.62 (SR/L);  
17.91 (UO-31/RC);  
24.77 (SNB-75/CNSC) 
IIb  67.91  22.46–108.67 
48.57 (MCF-7/BC); 
22.46 (T-47D/BC); 
28.68 (OVCAR-4/OC); 
37.30 (CCRF-CEM/L); 
36.53 (HL-60(TB)/L); 
39.61 (K-562/L); 
29.99 (MOLT-4/L); 
27.22 (RPMI-8226/L); 
37.26 (SR/L); 
32.01 (CAKI-1/RC); 
29.22 (UO-31/RC) 
IIc  88.37  45.30–164.67 
46.27 (HL-60(TB)/L);  
45.30 (K-562/L);  
44.68 (MOLT-4/L);  
39.40 (UO-31/RC) 
IIe  106.94  86.98–123.24 
86.98 (SNB-75/CNSC);  
90.19 (CAKI-1/RC);  
91.15 (UO-31/RC) 
IIf  104.78  87.84–129.52  87.84 (OVCAR-4/OC);  
89.17 (SNB-75/CNSC) 
ColC…colon cancer; M…melanoma; NSCLC…non-small cell lung cancer; RC…renal 
cancer; CNSC…CNS cancer; L…leukemia; BC…breast cancer; PC…prostate cancer; 
OV…ovarian cancer. 
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Two compounds (IIa  and  IIb) were tested in a  five concentrations  assay. A 48 h 
continuous drug exposure protocol was used with a SRB protein assay to estimate the cell 
viability and growth. Results (Tables 2 and 3) are expressed as pGI50, pTGI, pLC50. (GI50 – 
molar concentration of the compound that inhibits 50% net cell growth; TGI –  molar 
concentration of the compound leading to total inhibition of cell growth; LC50  –  molar 
concentration of the compound leading to 50% net cell death). Values were calculated for 
each of these parameters if the level of activity was reached; however, if the effect was not 
reached or was exceeded, the value was expressed as more or less than the maximum or 
minimum concentration tested. Furthermore, mean graph midpoints (MG_MID) were 
calculated for each of the parameters, giving an average activity parameter over all cell 
lines for each compound. For the calculation of the MG_MID, insensitive cell lines were 
included with the highest concentration tested. 
Tab. 2.   Cytotoxic activity of IIa & IIb in vitro full panel 60-cell line assay 
Cpd.  pGI50  pTGI  pLC50 
Range
a  MG_MID  Range
a  MG_MID  Range
a  MG_MID 
IIa  5.71 to 4.27 
6.10 to 4.78
b 
5.27 
5.25
b 
5.18 to 4.03 
5.49 to 4.14
b 
4.17 
4.31
b 
4.28 to 4.10 
5.08 to 4.34
b 
4.01 
4.05
b 
IIb  5.82 to 4.31 
6.55 to 4.13
b 
4.66 
4.94
b 
– 
– 
4.00 
4.02
b 
– 
– 
4.00 
4.00
b 
a values < 4.00 were excluded; 
b repeat assay. 
 
Tab. 3.   Cytotoxicity of the studied compounds against individual tumor cell lines  
Cpd.  Cancer type  Most sensitive 
cell lines  pGI50  pTGI  pLC50 
IIa 
Leukemia 
CCRF-CEM  5.64  5.20  < 4.00 
HL-60(TB)  5.90  5.49  5.08 
K-562  5.65  5.13  < 4.00 
MOLT-4  5.76  5.37  4.67 
RPMI-8226  5.74  5.28  < 4.00 
SR  5.70  5.17  < 4.00 
Non-small cell lung cancer  NCI-H322M  5.92  < 4.00  < 4.00 
Colon cancer  COLO 0205  5.73  5.36  4.99 
Melanoma  MALME-3M  6.10  5.30  < 4.00 
Renal cancer  TK-10  5.97  4.63  < 4.00 
Breast cancer  BT-549  5.83  4.52  < 4.00 
IIb 
Leukemia  K-562  5.59  < 4.00  < 4.00 
MOLT-4  5.56  < 4.00  < 4.00 
CNS cancer  SNB-75  5.72  < 4.00  < 4.00 
Renal cancer  CAKI-1  6.55  < 4.00  < 4.00 
Breast cancer  T-47D  5.63  < 4.00  < 4.00 
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The selectivity index (SI) obtained by dividing the full panel MG-MID (µM) of the compound 
IIa and IIb by their individual sub-panel MG-MID (µM) was considered as a measure of a 
compound’s selectivity. Ratios between 3 and 6 refer to moderate selectivity, ratios greater 
than 6 indicate high selectivity toward the corresponding cell line, while compounds not 
meeting either of these criteria are rated nonselective [39, 40]. The selectivity pattern 
showed that compounds possess the moderate level of selectivity to Leukemia panel at 
both the GI50 and TGI levels (Table 4). 
Tab. 4.   Anticancer selectivity pattern of the most active compounds at the GI50 (µM) 
and TGI (µM) levels. 
Cancer 
type 
GI50, µM
a  SI(GI50)
a  TGI, µM
a  SI(TGI)
a 
IIa  IIb  IIa  IIb  IIa  IIb  IIa  IIb 
Leukemia  1.89 
2.97 
3.73 
3.61 
2.40 
2.31 
8,00 
13.6 
5.35 
15.30 
>100 
>100 
12.38 
5.14 
0.99 
1.00 
NSC lung 
cancer 
3.65 
10.49 
49.77 
52.07 
1.24 
0.66 
0.60 
0.95 
90.59 
87.02 
>100 
>100 
0.76 
0.89 
0.99 
1.00 
Colon 
cancer 
3.57 
4.08 
19.74 
34.32 
1.27 
1.69 
1.51 
1.43 
65.19 
66.32 
>100 
>100 
1.05 
1.16 
0.99 
1.00 
CNS 
cancer 
5.42 
7.31 
42.23 
75.70 
0.84 
0.94 
0.71 
0.65 
89.98 
97.50 
>100 
>100 
0.76 
0.79 
0.99 
1.00 
Melanoma  3.74 
8.26 
15.07 
53.31 
1.21 
0.83 
2.00 
0.92 
23.33 
68.20 
>100 
>100 
2.94 
1.13 
0.99 
1.00 
Ovarian 
cancer 
5.97 
7.07 
46.95 
84.65 
0.76 
0.97 
0.64 
0.58 
>100 
87.14 
>100 
>100 
0.69 
0.88 
0.99 
1.00 
Renal 
cancer 
3.79 
4.43 
17.32 
40.00 
1.20 
1.55 
1.72 
1.23 
71.53 
80.38 
88.52 
>100 
0.96 
0.96 
1.12 
1.00 
Prostate 
cancer 
9.63 
8.26 
52.25 
53.43 
0.47 
0.83 
0.57 
0.92 
92.90 
>100 
>100 
>100 
0.74 
0.77 
0.99 
1.00 
Breast 
cancer 
3.47 
5.48 
21.47 
45.70 
1.31 
1.25 
1.39 
1.07 
77.55 
92.35 
>100 
>100 
0.88 
0.83 
0.99 
1.00 
a repeat assay. 
 
COMPARE Analysis 
NCI web-resources allow to compare selectivity patterns (mean graph fingerprints 
according DTP protocol) of the tested compounds with standard anticancer agents, and 
NCI active synthetic compounds and natural extracts, which are present in public available 
databases. Such analysis is based on the comparing the patterns of differential growth 
inhibition for cultured cell lines and can potentially gain insight into the mechanism of the 
cytotoxic action. If the data pattern correlates well with that of the compounds belonging to 
a standard agent database (Pearson’s correlation coefficient >0.6), the compound of 
interest may have the same mechanism of action. On the other hand, if the activity pattern 770  D. Kaminskyy et al.:   
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does not correlate with any standard agent, it is possible that the compound has a novel 
mechanism of action. Standard COMPARE analyses (http://dtp.nci.nih.gov/docs/compare/ 
compare.html) [41] were performed at GI50  level for IIa  and  IIb. Obtained correlation 
coefficients (r) didn’t allow distinguishing cytotoxicity mechanism of tested compounds with 
high probability. Nevertheless insignificant correlations with tamoxifen (NSC180973, r = 
0.545), caracemide (NSC253272, r = 0.528), as well as fluorodopan (NSC73754, r = 
0.533) for compound IIa and fluorodopan (NSC73754, r = 0.501) for IIb were detected. 
Interesting, that other 4-azolidinone derivatives also have significant value of correlation 
coefficients to the above mentioned substance [37, 38]. 
Experimental 
Chemistry 
Melting points were measured in open capillary tubes on a BUCHI B-545 melting point 
apparatus and are uncorrected. The elemental analyses (C, H, N) were performed using 
the Perkin–Elmer 2400 CHN analyzer and were within 0.4% of the theoretical values. The 
1H- and 
13C-NMR spectra were recorded on Varian Gemini 400 MHz or Bruker 125 MHz 
for frequencies 100 MHz in DMSO-d6  using tetramethylsilane as an internal standard. 
Chemical shifts are reported in ppm units with use of d scale. 
General method for preparation of spiro[3H-indole-3,2’-thiazolidine]-3’-aryl-2.4’(1H)-
diones (I) 
A mixture of isatin (10 mmol), the appropriate amine (10 mmol) and acetic acid (1 ml) in 
anhydrous benzene was refluxed for 2 hours. Thioglycolic acid (20 mmol) was added and 
the reaction mixture was refluxed with a Dean-Stark apparatus for 8 hours. After cooling, 
the reaction mixture was concentrated and added to a sat. NaHCO3 solution. The obtained 
product was filtered and recrystallized. 
3’-(4-Chlorophenyl)-spiro[3H-indole-3,2’-thiazolidine]-2,4'(1H)-dione  
(3'-(4-Chlorophenyl)-4'H-spiro[indole-3,2'-[1,3]thiazolidine]-2,4'(1H)-dione, Ia) 
Yield: 75%, mp 170–173°C (MeOH). 
1H NMR (400 MHz, DMSO-d6): 4.02 (d, J = 15.6 Hz, 
1H, CH2), 4.17 (d, J = 15.6 Hz, 1H, CH2), 6.78 (d, J = 7.7 Hz, 1H, isatin), 6.97–7.06 (m, 
3H, arom.), 7.24 (t, J = 7.6 Hz, 1H, isatin), 7.38 (d, J = 8.5 Hz, 2H, arom.), 7.53 (d, J = 7.4, 
Hz, 1H, isatin), 10.84 (s, 1H, NH). 
13C NMR (100 MHz, DMSO-d6,): 176.5, 172.31, 142.0, 
135.6, 133.3, 131.78, 130.9, 129.9, 126.9, 125.0, 123.3, 111.3, 69.9, 32.8. Anal. Сalcd for 
C16H11ClN2O2S, % C, 58.10; H, 3.35; N, 8.47. Found, %: C, 58.30; H, 3.55; N, 8.60. 
3’-(4-Hydroxyphenyl)-spiro[3H-indole-3,2’-thiazolidine]-2,4'(1H)-dione  
(3'-(4-Hydroxyphenyl)-4'H-spiro[indole-3,2'-[1,3]thiazolidine]-2,4'(1H)-dione, Ib) 
Yield: 62%, mp >230°C (DMF:EtOH, 1:1). 
1H NMR (400 MHz, DMSO-d6): 3.95 (d, J = 15.5 
Hz, 1H, CH2), 4.11 (d, J = 15.5 Hz, 1H, CH2), 6.62 (d, J = 8.6 Hz, 2H, arom.), 6.73 (d, J = 
7.7 Hz, 1H, isatin), 6.81 (d, J = 8.5 Hz, 2H, arom.), 7.01 (t, J = 7.5 Hz, 1H, isatin), 7.22 (t, J 
= 7.6 Hz, 1H, isatin), 7.53 (d, J = 7.4 Hz, 1H, isatin), 9.64 (s, 1H, OH), 10.71 (s, 1H, NH). 
13C NMR (100 MHz, DMSO-d6,): 176.8, 172.3, 157.7, 142.1, 131.5, 130.2, 127.6, 127.0, 
125.6, 123.1, 116.2, 111.0, 70.1, 32.7. Anal. Сalcd for C16H12N2O3S, % C, 61.53; H, 3.87; 
N, 8.97. Found, %: C, 61.70; H, 4.00; N, 9.10.   Spiro[Thiazolidinone-Isatin] Conjugates  771 
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General method for the preparation of 3’-aryl-5-arylidene- 
spiro[3H-indole-3,2’-thiazolidine]-2,4’(1H)-diones (II) 
A mixture of compound I (5 mmol), the appropriate aldehyde (5.5 mmol) and potassium 
tert-butylate (7.5 mmol) in iso-propanol was refluxed for 3 hours. The reaction mixture was 
cooled and acetic acid (1 ml) was added. The precipitate was filtered and recrystallized 
from an appropriate solvent. 
(5'Z)-3'-(4-Chlorophenyl)-5'-(phenylmethylidene)spiro[3H-indole-3,2'-thiazolidine]- 
2,4'(1H)-dione 
((5'Z)-5'-Benzylidene-3'-(4-chlorophenyl)-4'H-spiro[indole-3,2'-[1,3]thiazolidine]- 
2,4'(1H)-dione, IIa) 
Yield 63%, mp >230°C (i-PrOH). 
1H NMR (400 MHz, DMSO-d6): 6.81 (d, J = 7.7 Hz, 1H, 
isatin), 7.03 (t, J = 7.6 Hz, 1H, isatin), 7.12 (d, J = 8.8 Hz, 2H, arom.), 7.26 (t, J = 6.9, Hz, 
1H, isatin), 7.38–7.57 (m, 7H, arom.), 7.64 (s, 1H, PhCH=), 7.71 (d, J  = 7.5, Hz, 1H, 
isatin), 11.01 (s, 1H, NH). 
13C NMR (100 MHz, DMSO-d6,): 174.3, 166.6, 142.3, 135.1, 
134.7, 133.8, 132.3, 130.8, 130.0, 129.9, 129.6, 129.5, 127.3, 127.1, 124.6, 124.1, 123.7, 
111.5, 69.67. Anal. Сalcd for C23H15ClN2O2S, % C, 65.95; H, 3.61; N, 6.69. Found, %: C, 
66.10; H, 3.80; N, 6.95. 
(5'Z)-3'-(4-Chlorophenyl)-5'-[[4-(1-methylethyl)phenyl]methylene]spiro[3H-indole-3,2'-
thiazolidine]-2,4'(1H)-dione 
((5'Z)-3'-(4-Chlorophenyl)-5'-[4-(propan-2-yl)benzylidene]-4'H-spiro[indole-3,2'-
[1,3]thiazolidine]-2,4'(1H)-dione, IIb) 
Yield 68%, mp >230°C (AcOH). 
1H NMR (400 MHz, DMSO-d6): 1.20 (d, J = 6.9 Hz, 6H, 
2*CH3), 2.92 (m, 1H, CH), 6.83 (d, J = 7.8 Hz, 1H, isatin), 7.07 (t, J = 7.5 Hz, 1H, isatin), 
7.13 (d, J = 8.5 Hz, 2H, arom.), 7.30 (t, J = 7.6 Hz, 1H, isatin), 7.36 (d, J = 8.8 Hz, 2H, 
arom.), 7.44 (d, J = 8.5 Hz, 2H, arom.), 7.48 (d, J = 8.0 Hz, 2H, arom.), 7.63 (s, 1H, 
ArCH=), 7.71 (d, J = 7.4 Hz, 1H, isatin), 11.03 (s, 1H, NH). 
13C NMR (100 MHz, DMSO-
d6,): 174.4, 166.8, 150.2, 142.3, 135.2, 133.8, 132.3, 132.2, 130.8, 130.0, 129.9, 127.5, 
127.2, 127.1, 124.2, 123.6, 123.5, 111.5, 69.6, 33.8, 24.1. Anal. Сalcd for C26H21ClN2O2S, 
% C, 67.74; H, 4.59; N, 6.08. Found, %: C, 67.50; H, 4.75; N, 6.21. 
(5'Z)-5'-[[4-(Dimethylamino)phenyl]methylene]-3'-(4-hydroxyphenyl)spiro[3H-indole-3,2'-
thiazolidine]-2,4'(1H)-dione 
((5'Z)-5'-[4-(Dimethylamino)benzylidene]-3'-(4-hydroxyphenyl)-4'H-spiro[indole-3,2'-
[1,3]thiazolidine]-2,4'(1H)-dione, IIc) 
Yield 59%, mp >230°C (DMF:EtOH, 1:1). 
1H NMR (400 MHz, DMSO-d6): 2.97 (s, 6H, 
2*CH3), 6.65 (d, J = 8.6 Hz, 2H, arom.), 6.76–6.79 (m, 3H, arom., isatin), 6.85 (d, J = 8.6 
Hz, 2H, arom.), 7.06 (t, J = 7.5 Hz, 1H, isatin), 7.27 (t, J = 7.7 Hz, 1H, isatin), 7.37 (d, J = 
8.6 Hz, 2H, arom.), 7.47 (s, 1H, ArCH=), 7.64 (d, J = 7.4, Hz, 1H, isatin), 9.69 (s, 1H, OH), 
10.86 (s, 1H, NH). 
13C NMR (100 MHz, DMSO-d6,): 174.9, 167.3, 157.8, 150.8, 142.3, 
131.7, 131.4, 130.6, 127.3, 127.0, 125.4, 123.4, 122.2, 118.2, 118.1, 116.2, 112.5, 111.2, 
69.7. Anal. Сalcd for C25H21N3O3S, % C, 67.70; H, 4.77; N, 9.47. Found, %: C, 68.00; H, 
5.00; N, 9.63. 
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(5'Z)-3'-(4-Hydroxyphenyl)-5'-(3-phenyl-2-propenylidene)spiro[3H-indole-3,2'-thiazolidine]-
2,4'(1H)-dione 
((5'Z)-3'-(4-Hydroxyphenyl)-5'-(3-phenylprop-2-en-1-ylidene)-4'H-spiro[indole-3,2'-
[1,3]thiazolidine]-2,4'(1H)-dione, IId) 
Yield 72%, mp >230°C (AcOH). 
1H NMR (400 MHz, DMSO-d6): 6.57–6.70, 6.74–6.82, 
6.84–7.13, 7.17–7.41, 7.48–7.52 (5*m, 16H, PhCHCHCH, isatin, arom.), 9.68 (s, 1H, OH), 
10.87 (s, 1H, NH). 
3C NMR (100 MHz, DMSO-d6,): 174.6, 166.3, 157.9, 142.3, 139.2, 
136.7,131.9, 130.4, 130.2, 129.8, 129.5, 129.4, 129.3, 127.6, 127.2, 127.1, 126.3, 125.0, 
1234.4, 123.4, 116.2, 111.3, 69.7. Anal. Сalcd for C25H21N3O3S, % C, 67.70; H, 4.77; N, 
9.47. Found, %: C, 68.00; H, 5.00; N, 9.63. 
4-[(Z)-[1,2-Dihydro-3'-(4-hydroxyphenyl)-2,4'-dioxospiro[3H-indole-3,2'-thiazolidin]- 
5'-ylidene]methyl]-2-methoxy-benzeneacetic acid 
((4-{(Z)-[3'-(4-Hydroxyphenyl)-2,4'-dioxo-1,2-dihydro-5'H-spiro[indole-3,2'-[1,3]thiazolidin]-
5'-ylidene]methyl}-2-methoxyphenyl)acetic acid, IIe) 
Yield 64%, mp >230°C (MeOH). 
1H NMR (400 MHz, DMSO-d6): 3.86 (s, 1H, CH3O), 4.20 
(s, 2H, CH2O), 6.60–6.70, 6.78–6.95, 7.00–7.12, 7.17–7.31, 7.50–7.66 (5*m, 12H, arom., 
isatin), 9.81 (s, 1H, OH), 10.68 (s, 1H, NH). 
13C NMR (100 MHz, DMSO-d6,): 179.2, 176.1, 
167.3, 144.1, 143.2, 139.3 135.5, 135.1, 133.8, 133.3, 131.8, 130.3, 129.9, 129.2, 128.9, 
127.5, 127.0, 125.6, 124.8, 124.1, 111.1, 70.10, 61.3, 54.63. Anal. Сalcd for C26H20N2O7S, 
% C, 61.90; H, 4.00; N, 5.55. Found, %: C, 62.10; H, 4.21; N, 5.73. 
(5'Z)-5'-[(4-Bromophenyl)methylene]-3'-(4-hydroxyphenyl)spiro[3H-indole-3,2'-thiazolidine]-
2,4'(1H)-dione 
((5'Z)-5'-(4-Bromobenzylidene)-3'-(4-hydroxyphenyl)-4'H-spiro[indole-3,2'-[1,3]thiazolidine]-
2,4'(1H)-dione, IIf) 
Yield 68%, mp >230°C (AcOH). 
1H NMR (400 MHz, DMSO-d6): 6.79 (d, J = 7.7 Hz, 1H, 
izatin), 7.02 (t, J = 7.6 Hz, 1H, isatin), 7.21 (d, J = 8.4 Hz, 2H, arom.), 7.28 (t, J = 7.6, Hz, 
1H, isatin), 7.32 (d, J = 8.8 Hz, 2H, arom.), 7.40 (d, J = 8.8 Hz, 2H, arom.), 7.46 (d, J = 8.0 
Hz, 2H, arom.), 7.64 (s, 1H, ArCH=), 7.71 (d, J = 7.5 Hz, 1H, isatin), 9.81 (s, 1H, OH), 
10.79 (s, 1H, NH). 
3C NMR (100 MHz, DMSO-d6,): 174.6, 167.2, 142.1, 135.9, 135.1, 
134.2, 133.6, 132.1 131.6, 130.3, 129.6, 129.4, 128.0, 127.8, 124.4, 123.9, 123.5, 111.4, 
69.8. Anal. Сalcd for C23H15BrN2O3S, % C, 57.63; H, 3.15; N, 5.84. Found, %: C, 57.86; H, 
2.95; N, 5.58. 
General method for preparation of spiro[3H-indole-3,2’-thiazolidine]-2,4’(1H)-dione-
3’-alkanoic acids 
A mixture of amino acid ester hydrochloride (4 mmol), isatin (8 mmol), mercaptoacetic acid 
(12 mmol), triethylamine or Huning base (4 mmol) and molecular sieves (4 Å, 0.10 g) in 
ethanol (10 mL) was irradiated (Plazmatronica RM 800) with microwaves (power 100 W) at 
100 °С for 30 min (three 10 min cycles). After cooling, the reaction mixture was diluted with 
AcOEt (50 mL), sequentially washed with sat. NaHCO3, water, dried (MgSO4) and the 
solvent was removed in vacuo. The obtained product was purified by column chromate-
graphy (silica gel 60–230 meg, hexane:AcOEt, 1:1) and crystallized from EtOH. 
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1,2-Dihydro-2,4'-dioxospiro[3H-indole-3,2'-thiazolidine]-3'-acetic acid ethyl ester 
(Ethyl (2,4'-dioxo-1,2-dihydro-3'H-spiro[indole-3,2'-[1,3]thiazolidin]-3'-yl)acetate, Ic) 
Yield 68%, mp 131–133°C (EtOH). 
1H NMR (400 MHz, DMSO-d6): 1.07 (t, J = 7.2 Hz, 3Н, 
СН3), 3.39 (m, 2Н, СН2CH3), 3.96–3.99 (m, 4Н, 2*СН2), 6.92 (d, J = 7.8 Hz, 1H, isatin), 
7.07 (t, J = 6.6 Hz, 1H, isatin), 7.33 (m, 2Н, isatin), 10.83 (s, 1Н, NH). 
13C NMR (100 MHz, 
DMSO-d6,): 175.5, 171.8, 167.5, 142.4, 131.6, 126.7, 123.3, 122.5, 110.9, 68.3, 60.9, 
43.8, 32.0, 13.9. Anal. Сalcd for C14H14N2O4S, % C, 54.89; H, 4.61; N, 9.14. Found, %: C, 
55.03; H, 4.86; N, 9.08. 
1,2-Dihydro-2,4'-dioxospiro[3H-indole-3,2'-thiazolidine]-3'-propanoic acid methyl ester 
(Methyl 3-(2,4'-dioxo-1,2-dihydro-3'H-spiro[indole-3,2'-[1,3]thiazolidin]-3'-yl)propanoate, Id) 
Yield 75%, mp 114–116°C (EtOH). 
1H NMR (400 MHz, DMSO-d6): 2.33–2.40  (m,  2Н, 
СН2), 3.14–3.22 (m, 2H, CH2), 3.53 (s, 3Н, CH3), 3.71 (d, J = 15.2 Hz, 1Н, 5-Н), 3.93 (d, J 
= 15.2 Hz, 1Н, 5-Н), 6.93 (d, J = 7.7 Hz, 1H, isatin), 7.07 (t, J = 7.5 Hz, 1H, isatin), 7.30–
7.36 (m, 2Н, isatin), 10.73 (s, 1Н, NH). 
13C NMR (100 MHz, DMSO-d6,): 175.4, 172.3, 
168.6, 142.7, 131.4, 126.4, 123.5, 122.6, 111.1, 68.5, 61.3, 43.5, 33.1, 31.2. Anal. Сalcd 
for C14H14N2O4S, % C, 54.89; H, 4.61; N, 9.14. Found, %: C, 55.03; H, 4.86; N, 9.08. 
Cytotoxic activity against malignant human tumor cells  
Primary anticancer in vitro assay was performed at human tumor cell lines panel derived 
from nine neoplastic diseases, in accordance with the protocol of the Drug Evaluation 
Branch, National Cancer Institute, Bethesda [33–36]. Tested compounds were added to 
the culture at a single concentration (10
−5 M) and the cultures were incubated for 48 h. 
End point determinations were made with a protein binding dye, sulforhodamine B (SRB). 
Results for each tested compound were reported as the percent of growth of the treated 
cells when compared to the untreated control cells. The percentage growth was evaluated 
spectrophotometrically versus controls not treated with test agents.  
The cytotoxic and/or growth inhibitory effects of the most active selected compounds were 
tested in vitro against the full panel of about 60 human tumor cell lines at 10-fold dilutions 
of five concentrations ranging from 10
−4  to 10
−8  M. A 48-h continuous drug exposure 
protocol was followed and an SRB protein assay was used to estimate cell viability or 
growth. Using the seven absorbance measurements [time zero, (Tz), control growth in the 
absence of drug, (C), and test growth in the presence of drug at the five concentration 
levels (Ti)], the percentage growth was calculated at each of the drug concentrations 
levels. Percentage growth inhibition was calculated as: [(Ti − Tz) / (C − Tz)] x 100 for 
concentrations for which Ti ≥ Tz, [(Ti − Tz) / Tz] x 100 for concentrations for which Ti < Tz. 
Three dose response parameters were calculated for each compound. Growth inhibition of 
50% (GI50) was calculated from [(Ti  −  Tz)/(C  −  Tz)] x 100 = 50, which is the drug 
concentration resulting in a 50% lower net protein increase in the treated cells (measured 
by SRB staining) as compared to the net protein increase seen in the control cells. The 
drug concentration resulting in total growth inhibition (TGI) was calculated from Ti = Tz. 
The LC50 (concentration of drug resulting in a 50% reduction in the measured protein at 
the end of the drug treatment as compared to that at the beginning) indicating a net loss of 
cells following treatment was calculated from [(Ti − Tz)/ Tz] x 100 = -50. Values were 
calculated for each of these three parameters if the level of activity is reached; however, if 
the effect was not reached or was exceeded, the value for that parameter was expressed 774  D. Kaminskyy et al.:   
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as greater or less than the maximum or minimum concentration tested. The log GI50, log 
TGI, log LC50 were then determined, defined as the mean of the log’s of the individual GI50, 
TGI, LC50 values. The lowest values are obtained with the most sensitive cell lines. 
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